Compare CAAS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | ENTX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.9M | 147.4M |
| IPO Year | 2025 | 2015 |
| Metric | CAAS | ENTX |
|---|---|---|
| Price | $4.70 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 26.0K | ★ 3.6M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.97 | $13.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $0.91 |
| 52 Week High | $5.15 | $4.20 |
| Indicator | CAAS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 57.95 |
| Support Level | $4.38 | $1.10 |
| Resistance Level | $4.91 | $3.22 |
| Average True Range (ATR) | 0.21 | 0.32 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 53.09 | 13.81 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.